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ABSTRACT
Objective: Detection and resection of all malignant lesions is pivotal in staging 
and cytoreductive surgery (CRS) of endometrial cancer (EC). Intraoperative EC 
detection could be enhanced using OTL-38, a fluorescent-labelled folate receptor-α 
(FRα) targeted imaging agent. The objectives of this study were to investigate which 
subgroups of high-risk EC patients express FRα and assess feasibility of intraoperative 
EC detection using OTL-38. 
Results: FRα expression on TMA was significantly correlated with tumor type 
(p < 0.01). Eighty-two percent of serous and clear cell carcinomas showed FRα 
expression. Four patients were enrolled in the clinical study. Using fluorescence 
imaging all omental (n = 3) and lymph node (LN) metastases (n = 16) could be clearly 
identified, including one otherwise undetected omental metastasis. However, false-
positive fluorescence was identified in 17/50 non-metastatic LNs, caused by OTL-38 
targeting of FRβ, expressed by tumor-associated activated macrophages. 
Conclusions: This study describes high FRα expression in serous and clear cell 
EC and demonstrates the first experience of intraoperative FRα-targeted tumor 
detection in patients with these subtypes of EC. Although all metastases could be 
clearly identified using OTL-38, the role of tumor-associated macrophages should be 
further evaluated.
Methods: Immunohistochemical (IHC) staining of FRα expression was performed 
on tissue micro arrays (TMA) of 116 patients with high-risk EC features. Patients with 
either serous or clear cell EC, planned for staging or CRS, were eligible for inclusion 
in the clinical study and received an intravenous dose of 0.0125 mg/kg OTL-38, 
2-3 hours prior to surgery. Resected lesions, identified by standard-of-care and/or 
fluorescence imaging, were histopathologically assessed for FRα and tumor status.
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INTRODUCTION
Endometrial cancer (EC) can be categorized in type 
1 and type 2, based on etiology and clinicopathologic 
features [1]. Type 1 EC are commonly estrogen-
dependent, low-grade, endometrioid adenocarcinomas, 
accounting for 80% of all EC. Type 2 EC account for 
the remaining 20% and represent a more aggressive, 
high-grade tumor type with a poorer prognosis [2, 3]. 
These tumors are generally non-endometrioid, i.e. serous 
or clear cell, and unrelated to estrogen exposure. High-
risk EC is defined as a combination of several factors 
including non-endometrioid EC, more advanced disease 
stages/age, high-grade and lymphovascular space 
invasion [4]. Although EC is conventionally categorized 
in type I and II, improved understanding of the molecular 
landscape of EC has resulted in subdivision of EC in 
four molecular subtypes with improved prognostic 
significance, among others p53 mutant EC [5]. Each 
type and risk group of EC requires a different surgical 
approach because of distinctive tumor characteristics. 
For type I, low-grade EC the extent of pelvic organ 
resection and lymphadenectomy depends on the tumor 
stage, whereas a complete staging is recommended for 
clinically early stage serous and clear cell carcinomas, 
due to higher rates of metastatic disease [6]. A complete 
surgical staging includes a total hysterectomy with 
bilateral salpingo-oophorectomy (BSO), pelvic and para-
aortic lymph node sampling, omentectomy, and several 
peritoneal biopsies of predefined spots [7]. Depending 
on the presence of metastases during surgical staging, 
patients will either be monitored via follow-up or treated 
with adjuvant therapy [1]. 
Both during staging and cytoreductive surgery 
(CRS) of EC it is of utmost importance to identify tumor 
lesions with high accuracy. Surgeons are dependent on 
inspection and palpation (in case of open surgery) for 
intraoperative distinction between tumor and normal 
tissue. Histopathological analysis on frozen specimens 
obtained during the procedure can provide additional 
information, but is only performed on clinically suspicious 
lesions. Furthermore, non-suspect, but malignant lesions 
can easily be missed when visual inspection and palpation 
are the sole means for identification. An innovative 
technique that can assist in real-time intraoperative tumor 
detection is near-infrared (NIR) fluorescence imaging [8]. 
This technique is based on administration of a fluorescent 
agent and real-time detection of fluorescence using a 
dedicated NIR imaging system. A new era in the field of 
NIR fluorescence imaging has emerged with the clinical 
testing of tumor-targeted fluorescent contrast agents 
[9]. These agents consist of a tumor-targeting ligand, 
e.g. a peptide, antibody, nanobody etc., conjugated to a 
NIR fluorescent dye. One of the most promising agents 
currently available for clinical testing is OTL-38, a 
NIR fluorescent-labelled peptide targeting the Folate 
Receptor-α (FRα) [10]. The FRα, an isoform of the folate 
receptor, is anchored on the cell membrane and binds folic 
acid with high affinity. Expression of FRα on normal tissue 
is restricted to the apical surface of few epithelial tissues. 
However, marked overexpression in several tumor types, 
including EC, makes the FRα an attractive candidate for 
targeted imaging and therapy [11, 12]. 
Safety and feasibility of FRα-targeted tumor 
detection using OTL-38 have been demonstrated in 
ovarian and lung cancer [10, 13]. Application of OTL-38 
in EC surgery could be especially valuable in high-risk 
EC patients, who have a high likelihood of extra-uterine 
disease [7]. In these high-risk EC patients, real-time 
fluorescence guidance with OTL-38 during staging and 
CRS may provide enhanced visualization and detection 
of more metastatic lesions. The aim of this study was to 
assess which high-risk EC patients could benefit from 
FRα-targeted imaging. Although general overexpression 
of FRα in EC was previously described [12, 14], specific 
FRα expression in only high-risk EC patients, including 
both non-endometrioid and endometrioid EC, has not been 
demonstrated. Therefore, expression of FRα was assessed 
on a tissue micro array (TMA), consisting of 116 tissues 
derived from EC patients with high-risk features. Based on 
these results, feasibility of NIR fluorescence intraoperative 
tumor detection using OTL-38 was studied in patients with 
serous or clear cell EC, scheduled for staging or CRS.   
RESULTS
TMA-study 
Tissue cores of 101 patients were suitable for 
assessment of FRα expression. Clinicopathological 
characteristics and expression scores are shown in 
Table 1. Figure 1 shows representative examples of 
weak, moderate and strong intensity of FRα expression, 
in both endometrioid and non-endometrioid cancer. FRα 
expression was found in 63% of endometrioid cancers 
and in 82% of non-endometrioid cancers. Strong FRα 
expression was found in 38% of all endometrioid cancers 
compared to 46% of non-endometrioid cancers. A 
significant correlation (p < 0.01) between the pattern of 
FRα expression, i.e. homogenous vs. heterogenous, and 
tumor type was found. The majority of serous endometrial 
carcinomas (73%) showed homogenous FRα expression, 
while clear cell carcinomas showed a more heterogenous 
FRα expression pattern (65%). Endometrioid cancers 
showed both homogenous and heterogenous FRα 
expression in respectively 33% and 30% of all scored 
cases. Furthermore, a significant association between p53 
status, i.e. wildtype or mutant, and FRα expression was 
found (p = 0.01). All (11/11) homogenous FRα-expressing 




Four patients with EC (serous carcinoma; n = 3 and 
clear cell carcinoma; n = 1) were included in the clinical 
study (Table 2). Three patients underwent a staging 
procedure and one patient CRS. The patient undergoing 
CRS (patient #4) was diagnosed with a large mass in 
the fundus uteri (5.5 cm) and two suspect peritoneal 
depositions in the omentum (respectively 1.3 cm and 2.8 
cm) on preoperative computed tomography imaging. CRS 
consisted of uterus extirpation, BSO and omentectomy. 
Safety and pharmacokinetics
All patients received 0.0125 mg/kg OTL-38 over 
1 hour and no infusion was stopped or intermitted. Two 
patients experienced possibly related AEs: one patient 
experienced a mild muscle spasm and another patient 
mild pruritus. Both AEs were self-limiting. No clinically 
Table 1: Clinicopathologic patient characteristics in relation to FRα expression
 Total, n (%)  FRα expression in tumor cells, n (%)
 (n = 101)  absent heterogeneous homogenous P value
Age     
<60 33 (33%) 15 (45%) 13 (39%) 5 (15%) 0.057
60–70 26 (26%) 6 (30%) 11 (42%) 9 (35%)
>70 42 (42%) 11 (26%) 12 (29%) 19 (45%)
FIGO stage 2009
I 36 (36%) 15 (42%) 9 (25%) 12 (33%) 0.355
II 20 (20%) 5 (25%) 10 (50%) 5 (25%)
III 35 (35%) 9 (26%) 13 (37%) 13 (37%)
IV 9 (%) 3 (33%) 4 (44%) 2 (22%)
Tumor type
endometrioid 73 (72%) 27 (37%) 24 (33%) 22 (30%) 0.004
serous 11 (11%) 2 (18%) 1 (9%) 8 (73%)
clear cell 17 (17%) 3 (18%) 11 (65%) 3 (18%)
Grade
1 11 (11%) 3 (27%) 5 (45%) 3 (27%) 0.082
2 5 (5%) 0 (0%) 1 (20%) 4 (80%)
3 85 (84%) 29 (34%) 30 (35%) 26 (31%)
Depth of myometrial invasion
<50% 19 (20%) 4 (21%) 6 (32%) 9 (47%) 0.255
>50% 76 (80%) 28 (37%) 26 (34%) 22 (29%)
Lymphovascular space invasion
Absent 34 (40%) 15 (44%) 7 (21%) 12 (35%) 0.367
Present 48 (57%) 15 (31%) 19 (40%) 14 (29%)
unknown 2 (2%) 1 (50%) 1 (50%) 0 (0%)
p53 status, endometrioid cancer
Wildtype 56 (77%) 21 (38%) 20 (36%) 15 (27%) 0.472
Mutant 17 (23%) 6 (35%) 4 (24%) 7 (41%)
p53 status, non-endometrioid 
cancer
Wildtype 9 (32%) 3 (33%) 6 (67%) 0 (0%) 0.013
Mutant 19 (68%) 2 (11%) 6 (32%) 11 (100%)
Abbreviations: A description of the different staining patterns, i.e. absent, heterogenous and homogenous, is provided in the 
method section.
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relevant changes in blood pressure or pulse rate were 
observed. The maximal concentration for each dose 
was obtained directly after the end of the infusion. The 
elimination half-life was approximately 86 min. 
Intraoperative fluorescence imaging
Intraoperative fluorescence imaging allowed clear 
detection of tumor lesions using an exposure time of less 
than 60 ms. During surgery a fluorescent signal arising 
from the uterus could be detected in all patients with 
the primary tumor still in situ, with a mean tumor-to-
background ratio (TBR) of 6.4 (SD = 4.7; range: 2.9–13, 
Table 3). However, after slicing of the resected specimen, 
adjacent uterine tissue without tumor (#1 and #2) appeared 
more fluorescent than the signal arising from the tumor 
(Figure 2). In patient #4, almost no normal uterine tissue 
was present because of the bulky size of the tumor. The 
intraoperative fluorescence signal therefore probably 
originated from the primary tumor, instead of from normal 
uterine tissue. 
In two of four patients (#1 and #4) metastases were 
found in respectively 16/22 LNs and in three omental 
lesions. In the remaining two patients, no metastases were 
found during staging procedures. All histologically proven 
metastatic malignant lesions (19/19) could be identified 
by fluorescence imaging, with a mean TBR of 6.3 (SD 
= 4.5; range 3.2–14.1) in metastatic LNs (16/19) and a 
mean TBR of 2.3 (SD = 0.2; range 2.1–2.5) in omental 
metastases (3/19). Importantly, one omental lesion was 
not seen during visual inspection and only identified by 
fluorescence imaging. Histopathological analysis of this 
lesion revealed a small deposit of clear cell carcinoma. 
Fluorescence imaging enabled clear detection of all 
histologically proven metastatic LNs, even when these 
were located beneath a layer of peritoneum or other 
overlying tissue (Figure 2). 
Furthermore, a total of 50 LNs were resected that 
did not contain tumor cells. Seventeen out of these 50 LNs 
were detected by fluorescence imaging (patient #1, #2 and 
#3). Mean TBR of these false-positive LNs was 2.5 (SD 
= 1.3; range 1.5–6.2). No other false-positive lesions were 
identified, i.e. no fluorescence was detected in biopsies of 
the bladder, the diagraphm and recto-uterine (Douglas) 
pouch. Sensitivity, specificity and positive predictive value 
of fluorescence detection of LNs was 100% (16/16), 70% 
(39/56) and 48% (16/33) respectively. 
Histopathology
Histopathological analysis of EC lesions showed a 
circumferential staining pattern of FRα in malignant cells 
of both clear cell and serous cancer origin (Figure 3). FRα 
expression was also found in adjacent normal uterine 
epithelial cells and in adenomyosis tissue (patient #2, 
Figure 2), possibly explaining the weakened fluorescence 
intensity of uterine tumors compared to adjacent ‘normal’ 
uterine tissue. 
In all metastatic LNs, an intense FRα expression was 
seen in lymph node follicles, while expression in sinuses 
was weak (Figure 3). In contrast, FRα expression was 
absent in all (fluorescent) false-positive LNs. Additional 
Figure 1: Representative examples of FRα expression status in endometrioid and clear cell EC. Shown are tissue cores 
with respectively weak, moderate and strong intensity of FRα staining in endometrioid (A) and clear cell carcinoma (B). Magnification: 
10×.
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staining experiments however showed FRβ expression in 
the sinuses of these LNs which explained the false-positive 
fluorescence signal. The FRβ is expressed by activated 
macrophages and is also targeted by OTL-38 (Figure 4). 
DISCUSSION
Prior to the clinical study, we first performed a TMA 
study with tissue of EC patients with high-risk clinical 
Table 2: Patient and tumor characteristics of patients included in the clinical study
Patient No. Age Type of Surgery Diagnosis Primary tumor in situ
Suspicion metastatic 
disease
















Abbreviations: LNs = lymph nodes.
Figure 2: Fluorescence imaging of a primary uterine serous adenocarcinoma and of the metastatic lymph nodes. (A) 
Intraoperative identification of para-aortic, metastatic lymph nodes (dashed arrow), located beneath a layer of overlying tissue (patient #1). 
The normal arrow indicates the fluorescence signal arising from the uterus. (B) Ex vivo fluorescence imaging of the resected para-aortal 
lymph nodes (patient #1), that show a clear fluorescence signal. (C) Ex vivo fluorescence imaging of the bisected uterus (patient #1). The 
fluorescence signal, detected during surgery, appears to be mainly arising from normal adjacent background uterine tissue instead of the 
primary tumor. 
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Table 3: Relation between fluorescence imaging and final histopathology 
Patient 
No.









1 Malignant Yes* (3.2) Malignant (16/22)** Yes, all (6.3) Benign No Benign No
2 Malignant Yes*  (13) Benign Yes, some (3.0) Benign No Benign No
3 n/a n/a Benign Yes, some (1.8) Benign No Benign No
4 Malignant Yes* (2.9) n/a n/a Malignant*** Yes, all (2.4) n/a n/a
Abbreviations: n/a = not applicable; TBR = tumor-to-background, shown as mean; *a fluorescence signal arising from 
the uterus was seen during surgery **in 16/22 lymph nodes macrometastases were found; ***two omental depositions were 
identified on preoperative imaging, but during surgery a third lesion was identified solely by NIR fluorescence imaging. 
Final histopathological analysis showed tumor cells in all three omental lesions. 
Figure 3: Histopathological evaluation of resected lesions. (A) Immunohistochemical staining for FRα of a uterine tumor 
shows FRα expression in cancer cells (black arrow, patient #1) and in normal epithelial cells (dashed arrow). Magnification: 5×. 
(B) Immunohistochemical staining for FRα of non-malignant adenomyosis tissue of the uterus (patient #2). Magnification: 5×. 
(C) Immunohistochemical staining for FRα of a clinically suspect and fluorescent lymph node shows positive FRα expression in the lymph 
node follicels (patient #1). The FRα expression correlates with the presence of tumor cells. Magnification: 0.5×. (D) Immunohistochemical 
staining for FRα of a fluorescent omental lesion, that contained tumor cells, shows positive FRα expression (patient #4). Magnification: 2×.
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features to select those EC patients who may benefit 
most from FRα-targeted tumor imaging [4]. Optimally, 
selection of EC patients with homogenous FRα expression 
would result in targeting of all FRα-expressing tumor cells 
and consequently, low chances to miss tumor lesions in 
the clinical setting. A significant association between 
FRα expression and tumor type was shown, with positive 
expression in the majority of non-endometrioid cancers 
(82%). Remarkably, 73% of serous type EC showed 
homogenous FRα expression, which makes particularly 
this group of patients suitable for FRα imaging. Although 
a substantial part of high-risk EC patients (63%) also 
showed FRα expression, we chose to include only non-
endometrioid cancer patients in this clinical proof-of-
concept study. Non-endometrioid EC is by definition high-
grade and all these patients require staging or CRS. Several 
other studies support our findings and show upregulation 
of FRα in non-endometrioid EC and a correlation with 
tumor grade [12, 14, 15]. Limitations of the TMA part of 
this study are inherent to IHC analysis, such as variation 
in staining techniques, scoring systems and quality of 
antibodies. Notwithstanding, results of the current study 
corroborated results of the TMA study by Brown Jones 
et al. [14], who also showed a significant association 
between FRα overexpression and high-risk EC. Our study 
differs because FRα expression was evaluated among a 
subset of EC patients with high-risk features. Additionally, 
this is the first study to show a significant association 
between homogenous FRα expression and a mutant p53 
status in non-endometrioid EC. Routinely performed 
evaluation of the p53 status may therefore assist in patient 
selection for FRα-targeted agents. We did not perform 
a FRβ staining on the TMA, because previous literature 
describes that FRβ is more prevalent on stromal cells than 
on cancer cells [16, 17]. Yet, a systematic comparison 
between FRα and FRβ expression on endometrial cancer 
tissues with enough stromal tissue may be interesting.
The most important prognostic factor for EC 
survival is the presence of LN metastases. Therefore, 
pelvic and para-aortic lymph node sampling is 
recommended as an integral part of a surgical 
staging procedure for a subset of EC patients with a 
high likelihood of metastatic disease, such as non-
endometrioid EC patients [6]. The goal is to identify 
patients with nodal disease who will most likely benefit 
from adjuvant therapy [18]. The morbidity and mortality, 
costs and importantly, impact on patient survival 
associated with this procedure are however all subject to 
debate, especially in early stage EC patients [19]. In an 
attempt to better match the extent of the surgical staging 
procedure with the risk of LN metastasis, a surgical 
algorithm has recently been adopted for early stage EC 
patients [20]. Another method that has been advocated 
as alternative staging procedure is sentinel lymph node 
(SLN) mapping. Recently published results of a large 
multicenter SLN study suggest high accuracy of SLN 
Figure 4: Histopathological evaluation of a false-positive lymph node. Shown are a NIR fluorescence image, haematoxylin & 
eosin (HE) staining, and FRα and FRβ staining of a (fluorescent) LN that did not contain tumor cells. Fluorescence is mainly seen in the 
sinuses and not in the follicles. The magnified images (HE, FRα and FRβ) show the lack of FRα staining, while the sinuses show a positive 
FRβ staining. Magnifications: 1× and 10×.
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detection in 340 early EC patients using indocyanine 
green (ICG) as fluorescent tracer [21]. Cervical injection 
of ICG led to successful mapping of at least one SLN 
in 86% of patients and nodal metastases were correctly 
identified in 35 of 36 patients (97%). ICG is a safe and 
relatively inexpensive fluorescent dye, that has been 
extensively studied for SLN mapping in multiple tumor 
types, such as vulvar and cervical cancer [22, 23]. 
Although ICG proved its suitability as lymphatic tracer, 
it is not tumor-specific and does not bind to tumor cells. 
The use of ICG during gynecologic cancer surgery is 
therefore limited to the detection of SLNs. OTL-38 is an 
example of a tumor-targeted fluorescent tracer, that can 
selectively highlight tumor cells that express FRα [10]. 
OTL-38 has therefore the potential to aid gynecologists 
in real-time detection of distant metastases, i.e. peritoneal 
metastases, as well as more reliable removal of metastatic 
pelvic and para-aortic LNs. 
In the current study, all metastatic LNs were detected 
using fluorescence imaging with OTL-38. Importantly, 
LNs located below a layer of ± 1 cm of tissue, such as 
para-aortic LNs, could be clearly identified. Nevertheless, 
three out of four patients showed false-positive LNs during 
staging procedures. The fluorescence signal arising in 
those LNs appeared related to expression of FRβ, which 
is also targeted by OTL-38 as shown by histopathology 
evaluation. FRβ is selectively expressed on activated 
macrophages and is therefore explored as imaging target to 
detect lesions of inflammatory conditions [24]. Recently the 
role of FRβ in tumor tissues has been elucidated showing 
FRβ expression in tumor-associated macrophages [25]. In 
a study of thousand tumor sections, Shen et al. showed that 
FRβ is mainly expressed on tumor-associated macrophages 
in stromal cells [17]. Importantly, the percentage of 
positively stained cells correlated with tumor stage and LN 
involvement, suggesting that expression of FRβ might be 
an indication of the metastatic potential of a tumor. Further 
research is needed to clarify whether the apparently non-
malignant LNs identified with fluorescence imaging are 
involved in premetastatic niche formation. If so, resection 
of these LNs may yield clinical benefit. Thus, despite the 
fact that all metastatic LNs expressed FRα, the widespread 
implementation of OTL-38 for metastatic LN detection 
remains limited until the role of FRβ is elucidated. 
Although no clear intraoperative distinction between 
uterine tumor and background tissue could be made using 
OTL-38, this is not relevant in staging or CRS of EC 
because all patients undergo a total hysterectomy. Previous 
studies report on constitutive FRα expression on normal 
uterine epithelium, but high expression on various EC 
tumor tissues [12, 26]. An additional finding observed 
after histopathological analysis of uterine tissues was 
strong FRα expression in adenomyosis cells, which has 
been previously described in 17/18 endometriosis samples 
[27]. Since the aim of surgery in severe endometriosis 
patients is to resect all visible lesions, it is plausible that 
OTL-38 may enhance intraoperative detection in those 
patients, enabling better patient outcome. 
In conclusion, this study demonstrates the first 
application of OTL-38 for intraoperative tumor detection 
during staging and cytoreductive surgery in patients 
with either serous or clear cell EC. Prior to the clinical 
study, a TMA study on tissues from high-risk EC patients 
demonstrated a significant association between FRα 
expression and tumor type. In the clinical study, all 
malignant LNs and omental metastases could be clearly 
identified using OTL-38. However, until the role of FRβ 
in false-positive LNs is unambiguously established, the 




High-risk (stage IB-III) EC samples were collected 
from collaborating institutions within the TransPORTEC 
consortium, as previously described [4]. High-risk EC 
was defined using inclusion criteria for the PORTEC3 
study [28]. Specimen of 116 patients were included in this 
tissue micro array (TMA) study, and tissue microarrays 
contained 1-mm tumor and tumor/stroma cores in 
triplicate. Clinicopathological characteristics, including 
tumor type, stage, grade and p53 status of all cases have 
been described previously [4].
Immunohistochemical staining and evaluation
Immunohistochemistry was performed as described 
previously using the monoclonal antibody (Mab) 26B3.F2 
(certified Folate Receptor alpha IHC Assay Kit, Biocare 
Medical) [29]. The Mab26B3.F2 is highly specific for 
FRα without cross-reactivity to the other FR, e.g. FRβ, 
FRγ or FRδ. For validation of the staining protocol lung 
adenocarcinoma was used as positive control and normal 
liver as negative control. 
Blinded, independent evaluation of IHC staining 
was performed by two observers (L.B. and C.H.). 
Discrepancies were resolved by reviewing the relevant 
scores with a board certified pathologist (T.B.). A tumor 
core was rejected and not included in the analysis if 
it was missing or if >75% of the core was insufficient 
for evaluation. Staining was scored as absent/weak (0), 
moderate (1+) or strong (2+). A positive FRα expression 
was defined when >5% of tumor cells showed a moderate 
or strong FRα expression. A core was considered negative 
when none or <5% of tumor cells showed FRα expression. 
The overall intensity of staining of a case was recorded 
for the intensity that was seen in the majority of cores. 
Homogeneity was defined when all three cores showed 
similar intensity of FRα expression.  
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Clinical study
This trial was approved by the Medical Ethics 
Committee of the Leiden University Medical Center and 
was performed in accordance with the ethical standards 
of the Helsinki Declaration. Four patients with a high 
suspicion of primary serous or clear cell carcinoma, 
planned for either staging or CRS by laparotomy or 
laparoscopy, were included. Main exclusion criteria were 
pregnancy, history of anaphylactic reactions and impaired 
renal function (defined by eGFR < 50 ml/min/1.73 m2) or 
liver function (defined as values greater than 3× the upper 
limit of normal (ULN) for ALT, AST, or total bilirubin). 
Tracer administration and surgical procedure
Patients received a 1 hour intravenous infusion 
of 0.0125 mg/kg OTL-38, 2-3 hours before the start of 
surgery. The investigational product, OTL-38, has been 
extensively described [10]. Tolerability assessments 
(blood pressure, pulse, peripheral oxygen saturation, 
respiratory rate, ECG, temperature and skin assessments) 
and blood collection for pharmacokinetics and routine 
laboratory tests were performed regularly from just 
before administration up to 24 hours post-dosing. Adverse 
events (AEs) and use of concomitant medication were 
recorded. All surgical procedures were performed by an 
experienced gynecological oncologist. First the surgical 
field was searched for metastases by usual visual and 
tactile methods (the latter only in case of open surgery). 
Thereafter, the open or laparoscopic Artemis imaging 
system was used to identify NIR fluorescent lesions as 
described previously [30]. All tumor tissue identified, 
irrespective of the method, was resected if this was 
surgically feasible and clinically considered important 
by the operating gynecological oncologist. Each resected 
lesion was marked as fluorescent or non-fluorescent and 
as clinically suspected or not suspected for malignancy. 
Analysis
All resected lesions were routinely examined by an 
experienced pathologist for tumor status. A fluorescent 
tumor positive lesion was considered a true positive 
lesion, a fluorescent tumor negative lesion a false positive 
lesion and a non-fluorescent tumor positive lesion a false 
negative lesion. Additionally, immunohistochemical 
(IHC) staining for FRα was performed. IHC staining of 
FRβ was performed to evaluate the cause of false positive 
fluorescence. Placenta was used as positive control for 
FRβ staining. The negative control was assessed by using 
the secondary antibody only, without the primary antibody. 
Statistical and image analysis
Statistical analysis was performed using the IBM 
SPSS for Windows 20.0 software. Correlation of patient 
and tumor characteristics, including p53-status, with 
FRα expression was assessed with t-test for continuous 
variables and with χ2 test of Fisher’s exact test for 
categorical variables. In all statistical tests, a p-value of 
<0.05 was considered statistically significant. 
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